BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Elcelyx Therapeutics to Present Clinical Data on NewMet in Type 2 Diabetes at the 49th Annual European Association for the Study of Diabetes Meeting


9/17/2013 9:27:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Sept. 17, 2013 /PRNewswire/ -- Elcelyx Therapeutics today announced that clinical advisor, John Buse, M.D., Ph.D., will present clinical data for NewMet, a delayed-release formulation of generic metformin, in an oral presentation at the 49th Annual European Association for the Study of Diabetes (EASD) Meeting in Barcelona, Spain. Dr. Buse, Professor of Medicine and Director, Diabetes Care Center, Chief, Division of Endocrinology, Executive Associate Dean for Clinical Research at University of North Carolina School of Medicine, will describe the results of Elcelyx's Phase 2a clinical trial that compared NewMet with generic metformin in patients with Type 2 diabetes.

The presentation at the Fira Barcelona Gran Via, Bernard Hall will take place as follows:

Dissociation between metformin plasma exposure and its glucose-lowering effect: A novel gut-mediated mechanism of action

  • Date and Time: Thursday, September 26, 2013, 10:45 11:00 a.m. CEST
  • Category: OP 25 Novel therapeutic agents and insights
  • Oral Presentation #: 145
  • Presenter: John Buse, M.D., Ph.D., Professor of Medicine and Director, Diabetes Care Center, Chief, Division of Endocrinology, Executive Associate Dean for Clinical Research at University of North Carolina School of Medicine, Chapel Hill, North Carolina

About NewMet
Elcelyx Therapeutics' pharmaceutical product candidate NewMet is a delayed-release formulation of metformin, the foundational treatment for Type 2 diabetes. By redesigning generic metformin to target the lower bowel, NewMet dramatically reduces the amount of active ingredient in the bloodstream while still maintaining metformin's potent glucose lowering benefit. Phase 2a trial results indicate that a significantly lower once-daily dose of NewMet that maintains efficacy may meaningfully reduce metformin's gastrointestinal side effects and eliminate the need for titration to initiate treatment. NewMet's improved safety and tolerability profile may make it appropriate for use by Type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated due to renal impairment. A Phase 2b, 240-patient, multicenter dose-finding clinical trial is underway. The study has already met its primary endpoint with statistically significant reductions in fasting plasma glucose at four weeks of treatment compared to placebo. Secondary endpoints through 12 weeks include changes in fasting plasma glucose, hemoglobin A1c, body weight and measures of safety and tolerability. Twelve-week results are expected in late October.

About Elcelyx Therapeutics
Elcelyx Therapeutics is developing pharmaceutical product candidate NewMet for use by Type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. NewMet presents a near-term, blockbuster commercial opportunity. Elcelyx is based in San Diego, CA. For more information, visit www.Elcelyx.com.

SOURCE Elcelyx Therapeutics



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES